EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Etiopathogenesis and Emerging Methods for Treatment of Vitiligo

Tomasz Iwanowski iD, Karol Kołkowski iD, Roman Janusz Nowicki iD, Małgorzata Sokołowska-Wojdyło iD

International Journal of Molecular Sciences · 2023

DOI: 10.3390/ijms24119749 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Tomasz Iwanowski und 3 weiteren Autor:innen. Beteiligte Einrichtung: Dermedica, Aleja Zwycięstwa 34, 80-219 Gdansk, Poland. Hauptthemen laut MEDLINE: Vitiligo, Janus Kinase Inhibitors. Die Arbeit wurde bisher 35-mal zitiert (Crossref) und nennt 76 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Polish Ministry of Science and Higher Education and Medical University of Gdańsk, Polish Ministry of Science and Higher Education, Medical University of Gdańsk.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Vitiligo is an acquired chronic depigmenting disorder of skin. It is mostly asymptomatic and characterized by amelanotic macules and patches that affects 0.5% to 2% of the world’s population. The etiology of vitiligo has not been clearly elucidated and multiple theories have been proposed regarding the causes of the disorder. Among the most prevalent theories, the genetic predisposition, oxidative stress theory, promotion of cellular stress and pathologic influence of lymphocytes T have been highlighted. As a result of increases in in-depth knowledge concerning the pathogenetic processes in vitiligo, we review the most recent information concerning its etiopathogenesis and treatment methods including topical and oral Janus kinase inhibitors, prostaglandins and their analogues, namely afamelanotide, Wnt/β-catenin-signaling agonists and cell-based therapies. Topical ruxolitinib has been registered for vitiligo treatment, whereas other agents as oral ritlecitinib, afamelanotide and latanoprost have been studied in ongoing clinical trials. New highly effective therapeutic strategies may be developed thanks to molecular and genetic studies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

VitiligoJanus Kinase InhibitorsHumansProtein Kinase InhibitorsSkinProstaglandins

Stichwörter der Autor:innen

Janus kinase inhibitorspathogenesistreatmentvitiligo

Substanzen

Janus Kinase InhibitorsProtein Kinase InhibitorsProstaglandins

Autor:innen und Institutionen

  • Dermedica, Aleja Zwycięstwa 34, 80-219 Gdansk, Poland.
  • Dermatological Students Scientific Association, Department of Dermatology, Venerology and Allergology, Faculty of Medicine, Medical University of Gdansk, 80-214 Gdansk, Poland.
  • Department of Dermatology, Venerology and Allergology, Faculty of Medicine, Medical University of Gdansk, 80-214 Gdansk, Poland.

ORCID-Profile: Tomasz Iwanowski, Karol Kołkowski, Roman Janusz Nowicki, Małgorzata Sokołowska-Wojdyło

Förderung

  • Polish Ministry of Science and Higher Education and Medical University of Gdańsk
  • Polish Ministry of Science and Higher Education
  • Medical University of Gdańsk

Zitieren

APA

Iwanowski, T., Kołkowski, K., Nowicki, R. J., & Sokołowska-Wojdyło, M. (2023). Etiopathogenesis and Emerging Methods for Treatment of Vitiligo. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms24119749

Vancouver

Iwanowski T, Kołkowski K, Nowicki RJ, Sokołowska-Wojdyło M. Etiopathogenesis and Emerging Methods for Treatment of Vitiligo. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms24119749

BibTeX
@article{Iwanowski2023,
  author = {Iwanowski, Tomasz and Kołkowski, Karol and Nowicki, Roman Janusz and Sokołowska-Wojdyło, Małgorzata},
  title = {Etiopathogenesis and Emerging Methods for Treatment of Vitiligo},
  journal = {International Journal of Molecular Sciences},
  year = {2023},
  doi = {10.3390/ijms24119749}
}
Kostenlos starten →